Technology
Health
Biotechnology
IMV
$3.719876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$3.71
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.11 (3.06%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell IMV and other stocks, options, ETFs, and crypto commission-free!
About
IMV Inc. Common Shares, also called IMV, is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. Read More The firm's patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada.
CEO
Employees
â
Headquarters
Halifax, Nova Scotia
Founded
2000
Market Cap
161.93M
Price-Earnings Ratio
â
Dividend Yield
0.00
Average Volume
11.65K
High Today
$3.91
Low Today
$3.68
Open Price
$3.80
Volume
7.85K
52 Week High
$7.21
52 Week Low
$3.60
Collections
Technology
Health
Biotechnology
Medical
Biopharmaceutical
Cancer Prevention
Pharmaceutical
2018 IPO
News
Markets Insider22h
IMV Inc. to Present at Two Upcoming Investor Conferences
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company, today announced that IMV Chief Executive Officer Frederic Ors will present at the Spring Investor Summit and the HC Wainwright Global Life Sciences Conference during April 2019. Details on each conference and presentation are as follows: ⢠Venue: Spring Investor Summit, being held April 1-2, 2019 ⢠Date of Presentation: Monday, April 1 ⢠Time: 8:30 a.m. ET ⢠Location: JW Marriott Hotel, Essex House, New York City ⢠Venue: HC Wainw...
Seeking AlphaMar 22
IMV INC (IMMVD) CEO Fred Ors on Q4 2018 Results - Earnings Call Transcript
IMV INC (OTCQX:IMMVD) Q4 2018 Earnings Conference Call March 22, 2019 8:00 AM ET Company Participants Pierre LabbĂŠ - CFO Fred Ors - CEO Stephan Fiset - VP, Clinical Research Conference Call Participants David Novak - Raymond James Andre Uddin - Mackie Research Capital Endri Leno - National Bank Doug Loe - Echelon Wealth Partners Operator Good day, ladies and gentlemen, and welcome to the IMV 2018 Earnings Call. At this time, all lines are in a listen-only mode. Later we will conduct a question-an...
BusinessWireMar 21
IMV Inc. Announces 2018 Year-end Financial and Operational Results and Provides Updates on Key Clinical Programs
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today released its financial and operational results for year ending December 31, 2018. âIMV made significant advances in 2018,â said Frederic Ors, Chief Executive Officer. âFoundational changes, including shifting the name of the corporation to IMV and listing on Nasdaq, are enabling us to access to a larger pool of investors and allow us to better communicate our value proposition glob...
Price Paid on Robinhood
12% Lower
Right Now
52 Week Low
$3.60
Average Price Paid
$4.21
52 Week High
$7.21